A technical and commercial intelligence guide to complex generic development, patent strategy, regulatory sequencing, and emerging market positioning for pharma […]

The generic drug industry operates on a paradox that never fully resolves. Generic and biosimilar medicines fill 90% of all

Forty years after Congress passed the Drug Price Competition and Patent Term Restoration Act of 1984, the law’s core tension

The Orange Book and Purple Book are not regulatory housekeeping. They are the official ledgers where billions of dollars of

More than $200 billion in pharmaceutical revenue faces patent expiry through 2030, with some analyst projections reaching $300 billion. For

Generic drugs account for 90% of U.S. prescriptions yet only 17.5% of total drug spending. That math is possible because

The gap between developing a generic drug and a biosimilar is not regulatory paperwork. It is the difference between a

Why the Patent Cliff Is the Pharmaceutical Industry’s Most Predictable Crisis — and the Generic Industry’s Biggest Opportunity Every dollar

When Paragraph IV filings hit the docket, they set off a chain of financial events most analysts only half-understand. Here